{"id":"W2012098025","doi":"10.3109/10428194.2010.546015","title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Alberta Cancer Foundation; University Health Network; Queen Elizabeth II Health Sciences Centre; Juravinski Hospital","funders":"National Cancer Institute","keywords":"Gemcitabine; Bortezomib; Mantle cell lymphoma; Medicine; Internal medicine; Oncology; Adverse effect; Chemotherapy; Refractory (planetary science); Phases of clinical research; Lymphoma; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002358475,0.00138546,0.00269312,0.0006682424,0.0006946046,0.0008226277,0.001193004,0.001451112,0.004278901],"category_scores_gemma":[0.00117713,0.0006731973,0.001093055,0.001004569,0.0009423188,0.0004587578,0.000415072,0.003316871,0.0006970433],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002086425,"about_ca_system_score_gemma":0.005674209,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01121041,"about_ca_topic_score_gemma":0.04131997,"domain_scores_codex":[0.9991851,0.0004598987,0.00003223682,0.00008196285,0.00009809435,0.0001425645],"domain_scores_gemma":[0.9991168,0.0001108836,0.000141351,0.00004695434,0.00006519126,0.000518801],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8350536,0.04586967,0.006274846,0.0007945822,0.001282023,0.0003652007,0.0002037039,0.001471256,0.01838541,0.0003286451,0.007371852,0.08259922],"study_design_scores_gemma":[0.7946222,0.1911983,0.007489363,0.00003526477,0.0003389865,0.0001823972,0.0000297022,0.000460239,0.000944391,0.00008710121,0.004595288,0.00001665744],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.960577,0.01199333,0.0007514734,0.001498961,0.0003127449,0.01503011,0.003124395,0.0001633639,0.006548725],"genre_scores_gemma":[0.9414753,0.01003966,0.006897816,0.003508933,0.0005002335,0.01868824,0.008556522,0.00006490409,0.01026835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01121041,"threshold_uncertainty_score":0.02229035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07482145748558373,"score_gpt":0.3398540940634834,"score_spread":0.2650326365778997,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}